Dr. Michael Corey has fifteen years of experience in biotechnology beyond his doctoral training. His initial conception of the coupled luminescent cytotoxicity assay in the late 1990s led to an expanding array of applications, publications, and intellectual property, including the fundamental patent on one-step coupled luminescent cytotoxicity assays (US Patent #6811990). He reported an extremely rapid, ultra-sensitive phosphate/phosphatase assay at the Intelligent Drug Discovery conference in 2002 as an invited speaker, and up-to-date coupled luminescent methods were published with Dr. R. J. Kinders in Chapter 16 of the Drug Discovery Handbook (Wiley & Sons, 2005). Dr. Corey’s coupled luminescent technology is currently licensed exclusively to Cell Technology, Inc., including assays of cytotoxicity by G3PDH and LDH release, phosphate/phosphatase activity, acetylcholinesterase activity, and several methods in late-stage development.

Dr. Corey’s other scientific interests include fluorescence technology and assay development, oncology, virology, cytotoxic T cells, innate immunity (including complement), protein separation and analysis, novel applications of PCR, and automated data reduction and analysis. In addition to his scientific work, Dr. Corey has four literary publications and speaks fluent English, French, Japanese, and Czech. Dr. Corey obtained his B.A. from Harvard University and his Ph.D. in Biochemistry from the University of California, Berkeley.

Dr. Steve Sherwood has over 20 years of experience in the field of cell Biology, beyond his doctoral training. He brings a wealth of knowledge in cell based assay development, and has over 40 publications and 9 patents. He has held lead positions at Applied Biosystems, Genencor, Geron Corp, Molecular Probes, Genentech and Stanford University.

Dr. Sherwood’s interests include Drug discovery and translational research, cell cycle, apoptosis, mitotsis as a drug target, mechanism of action of antiproliferative Mab’s and small molecules and immunomodulatory agents, pharmacodynamic evaluation of small molecule and antibody therapeutics, diagnostics, fluorescence-based cell analysis technologies, in-vivo imaging and drug activity, technology development. Metronomic drug dosing theory and practice, nanoparticle drug delivery.

Dr. Shrewood obtained his PhD from the University of California, Berkeley, and completed his postdoctoral fellowships from The University of Michigan, Ann Arbor, and Stanford University.